MSFC: Multiple Sclerosis Functional Composite

No, MSFC requires in-person administration due to need for equipment (pegboard, stopwatch, audio recording) and direct observation of patient performance for safety and validity. T25FW must be supervised to prevent falls in patients with balance impairment; 9-HPT requires pegboard setup and observation; PASAT requires standardized audio presentation. Remote administration introduces uncontrolled variables (environment, equipment variation) invalidating comparison to normative data. Use EDSS or patient-reported scales (MSWS-12) for remote assessment.

Typical PASAT practice effect is 2-5 correct responses on first retest (improvement even without treatment); this diminishes on subsequent tests. To minimize practice effects in research: (a) use ≥6 month intervals between test occasions; (b) administer alternate PASAT versions if available (different digit sequences); (c) document test interval and number of prior PASAT exposures; (d) expect minimal change (<3 points) at <6 month intervals. Single baseline PASAT without prior exposure provides most valid baseline; post-treatment change interpretation requires knowledge of prior exposure history.

MSFC composite change ≥0.5 equals approximately 1 SD change in one component and is considered clinically meaningful. This can represent T25FW improvement of ~3-4 seconds, 9-HPT improvement of ~5-7 seconds, or PASAT improvement of ~5-10 correct responses (depending on baseline). Individual component changes <0.2-0.3 fall within test-retest variability and should not be interpreted as real change. Context matters: improvement >0.5 in clinical trial setting suggests treatment effect, while >0.5 deterioration in natural history suggests disease progression.

Yes, MSFC can be administered in primary progressive (PPMS) and secondary progressive (SPMS) MS. However, floor effects limit utility in advanced PPMS where patients cannot walk 25 feet or have severe ataxia preventing peg test completion. MSFC is most useful in early-progressive disease (EDSS 4-6) where walking and coordination remain testable. For EDSS >7, MSFC may not be feasible; EDSS and MRI remain primary outcomes in advanced progressive MS trials.

MSFC composite scores are z-scores centered at 0. Population average is 0 with SD approximately 1.0. Typical values: MSFC +1.0 to -1.0 = normal function; -1.0 to -2.0 = mild impairment; <-2.0 = significant impairment. Normative database stratified by age (20-70) and sex; use age-matched normative data for z-score calculation. Example: 40-year-old woman with T25FW 8 sec (0.1 SD above mean), 9-HPT 28 sec (-0.3 SD), PASAT 45 correct (-0.4 SD) yields MSFC approximately -0.2 (mild impairment). Consult published normative tables or use MSFC calculator software for accurate z-score conversion.